{
    "root": "3490033f-0c0c-bf3d-e063-6294a90a17da",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phentermine Hydrochloride",
    "value": "20250507",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PHENTERMINE HYDROCHLORIDE",
            "code": "0K2I505OTV"
        }
    ],
    "indications": "Phentermine hydrochloride capsules are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m\n       \n \n  2, or ≥ 27 kg/m\n       \n \n  2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).\n      \n\n \n                  Below is a chart of body mass index (BMI) based on various heights and weights.\n                  BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.\n                  \n                     BODY MASS INDEX (BMI), kg/m\n                     \n                        2\n                     \n                  \n                  \n                  The limited usefulness of agents of this class, including phentermine, [se\n       \n \n  e \n                     CLINICAL PHARMACOLOGY (\n       \n \n  12.1\n                     , \n                     12.2)] should be measured against possible risk factors inherent in their use such as those described below.",
    "contraindications": "Dosage should be individualized to obtain an adequate response with the lowest effective dose. ( 2.1 ) Late evening administration should be avoided (risk of insomnia). ( 2.1 ) Phentermine hydrochloride capsules can be taken with or without food ( 2.1 ) Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73m 2 )- ( 2.2 )",
    "warningsAndPrecautions": "Phentermine hydrochloride capsules USP, for oral administration, are available as:\n                  \n                     30 mg:  Blue/Clear powder filled capsules; imprinted “N16” in black ink and supplied as:\n  \n                     \nNDC 72789-287-14 bottles of 14\n  \nNDC 72789-287-28 bottles of 28\n  \nNDC 72789-287-30 bottles of 30\n \n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  Protect from moisture.\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  Keep out of the reach of children.",
    "adverseReactions": "• History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)\n       \n \n  • During or within 14 days following the administration of monoamine oxidase inhibitors\n       \n \n  • Hyperthyroidism\n       \n \n  • Glaucoma\n       \n \n  • Agitated states\n       \n \n  • History of drug abuse\n       \n \n  • Pregnancy [see \n       \n \n  USE IN SPECIFIC POPULATIONS (\n       \n \n  8.1)]\n       \n \n  • Nursing [see \n       \n \n  USE IN SPECIFIC POPULATIONS (\n       \n \n  8.3)]\n       \n \n  • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines"
}